Viriom Selects ChemDiv To Develop HIV Program

Main Category: HIV / AIDS
Article Date: 19 Oct 2009 - 13:00 PDT

email to a friend   printer friendly   opinions  

ChemDiv, Inc. (ChemDiv) of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

Viriom has recently signed the license agreement with Roche. Under the terms of this agreement Roche granted Viriom development and commercialization rights for potential novel HIV/AIDS medicine in Russia, Ukraine, Belarus and Kazakhstan. Subject to performance of the program Viriom will also receive license fees, development milestones and royalties on worldwide sales.

Vadim Bichko, Vice President Virology at ChemDiv, Inc., said: "We are excited about this new collaboration with Viriom and Roche. These novel HIV inhibitors have shown excellent antiviral properties in vitro, good bioavailability, PK and safety profiles, as well as a high genetic barrier to resistance. Based on pre-clinical studies to date, these molecules have the potential to become best in class HIV drugs."

About VIRIOM

VIRIOM Ltd. is an innovative company that was established in 2009 to develop targeted medicines for HIV/AIDS. Basis is the Center of High Technologies ChemRar to which VIRIOM is affiliated. VIRIOM is planning to conduct research and clinical trials in Russia using the experience and knowledge of Russian scientists. Chemical Diversity Research Institute, Prudentas Ltd. and Drug Technologies Ltd.of ChemRar Hi Tech Center (ChemRar) as well as Moscow City Center for prevention and treatment of HIV/AIDS were selected as partners in this program.

About ChemDiv, Inc.

ChemDiv collaborates with pharmaceutical and biotech partners by enabling them to accelerate their R&D programs to higher value clinical inflection points. ChemDiv provides integrated drug discovery and early clinical development, extracting value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.

ChemDiv is the only vertically and horizontally integrated discovery and development CRO headquartered in San Diego, CA, with: unique access to the Eastern European emerging pharma market; rational drug design and medicinal chemistry in a broad range of therapeutic areas of target classes; world's largest small molecule inventory; working with 20 top pharma and 100 top biotechs in all major markets.

With its successful 20 year business record in life sciences and over 500 research associates equivalent employed globally, ChemDiv has successfully prosecuted fully integrated programs from target to Proof of Concept (POC) and market registration.

About Chemical Diversity Research Institute.

CDRI is a contract research organization focused on pre-clinical and clinical R&D. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing the highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource™ platforms. Discovery outSource™ platform solutions cover the complete range of disciplines from identification of a biological target (protein expression, assay development etc.); to clinical drug candidates (ADME/DMPK, toxicity and safety studies, in vivo animal models, drug formulation etc.); to drug development candidate (Phase I to Phase IV).

Source
ChemRar Hi Tech Center

• Additional
• References
• Citations